BOCA RATON, Fla., Feb. 6 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals
(Nasdaq: NABI) today announced it will hold a conference call on Wednesday,
February 8, 2006 at 4:30 pm EST. Thomas H. McLain, chairman, chief executive
officer and president; Raafat Fahim, Ph.D., senior vice president, research,
technical and production operations; and Henrik Rasmussen, M.D., Ph.D., senior
vice president, clinical, medical and regulatory affairs, will discuss the
technical aspects of the company's various pipeline programs including NicVAX,
Civacir and its S. epidermidis Vaccine.
As previously announced, the operational review of Nabi
Biopharmaceuticals' 2005 fourth quarter and year-end financial results will
take place on Thursday, February 23, 2006 at 4:30 pm EST.
The February 8th live webcast can be accessed at
http://invite.mshow.com/findshow.aspx?usertype=0&cobrand=100&shownumber=289344
or via the Nabi Biopharmaceuticals website http://www.nabi.com. If you do not
have Internet access, the U.S./Canada call-in number is 877-569-0953
conference code 5227223, and the international call-in number is 706-634-4967
conference code 5227223. An audio replay will be available for U.S./Canada
callers at 800-642-1687 conference code 5227223, and for international callers
at 706-645-9291 conference code 5227223.
An archived version of the webcast will be available at the same Internet
address through March 2, 2006. The audio replay will also be available
through March 2, 2006.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering
the immune system to develop and market products that fight serious medical
conditions. We are focusing on developing products addressing commercial
opportunities in our core business areas: Gram-positive bacterial infections,
hepatitis, kidney disease (nephrology), and nicotine addiction. We have three
products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R)
[Hepatitis B Immune Globulin (Human)], and Aloprim(TM) [Allopurinol sodium
(for injection)] and a number of products in various stages of clinical and
pre-clinical development. The company also filed Marketing Authorization
Applications (MAA) in Europe to market Nabi-HB(R) Intravenous [Hepatitis B
Immune Globulin (Human) Intravenous] under the trade name HEBIG(TM) for the
prevention of hepatitis B disease in HBV-positive liver transplant patients;
and for PhosLo, which is already marketed in the United States. The company's
products in development include NicVAX(TM) (Nicotine Conjugate Vaccine), a
vaccine to treat nicotine addiction, and Civacir(TM) [Hepatitis C Immune
Globulin (Human)], an antibody for preventing hepatitis C virus re-infection
in liver transplant patients. For additional information on Nabi
Biopharmaceuticals, please visit our website: http://www.nabi.com.
SOURCE Nabi Biopharmaceuticals
 back to top
Related links:
http://www.nabi.com
CONTACT:
Thomas E. Rathjen, Vice President of Investor
Relations for Nabi Biopharmaceuticals, +1-561-989-5800, or
http://www.nabi.com
|
